Spots Global Cancer Trial Database for tumor regression
Every month we try and update this database with for tumor regression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer | NCT04741204 | Breast Cancer S... Insulin Resista... Racial Bias | Metformin Exten... | 18 Years - 80 Years | Woman's | |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748 | Metastatic Mela... Metastatic Rena... Metastatic Canc... | Anti-NY ESO-1 T... aldesleukin Cyclophosphamid... fludarabine pho... ALVAC NY ESO-1 ... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | NCT00612222 | Metastatic Mela... Skin Cancer | autologous anti... ALVAC MART-1 Va... aldesleukin cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | NCT01967823 | Melanoma Meningioma Breast Cancer Non-Small Cell ... Hepatocellular ... | Anti-NY ESO-1 m... Cyclophosphamid... Fludarabine Aldesleukin | 15 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer | NCT00923806 | Metastatic Canc... | PG13-CEA_TCR (A... Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer | NCT04741204 | Breast Cancer S... Insulin Resista... Racial Bias | Metformin Exten... | 18 Years - 80 Years | Woman's | |
| Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | NCT00610311 | Metastatic Mela... Skin Cancer | cyclophosphamid... fludarabine pho... Aldesleukin ALVAC gp100 Vac... anti-gp100:154-... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | NCT00610311 | Metastatic Mela... Skin Cancer | cyclophosphamid... fludarabine pho... Aldesleukin ALVAC gp100 Vac... anti-gp100:154-... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | NCT00612222 | Metastatic Mela... Skin Cancer | autologous anti... ALVAC MART-1 Va... aldesleukin cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer | NCT04741204 | Breast Cancer S... Insulin Resista... Racial Bias | Metformin Exten... | 18 Years - 80 Years | Woman's | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer | NCT04741204 | Breast Cancer S... Insulin Resista... Racial Bias | Metformin Exten... | 18 Years - 80 Years | Woman's | |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | NCT02111850 | Cervical Cancer Renal Cancer Urothelial Canc... Melanoma Breast Cancer | Anti-MAGE-A3-DP... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | NCT01160445 | Metastatic Mela... Metastatic Rena... | Zanolimumab Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | NCT03480152 | Melanoma Colon Cancer Gastrointestina... Genitourinary C... Hepatocellular ... | National Cancer... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | NCT02111850 | Cervical Cancer Renal Cancer Urothelial Canc... Melanoma Breast Cancer | Anti-MAGE-A3-DP... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
